Sierra Oncology (Sierra Oncology) EPS (Diluted) : $-6.77 (TTM As of Mar. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Sierra Oncology EPS (Diluted)?

Sierra Oncology's Earnings per Share (Diluted) for the three months ended in Mar. 2022 was $-1.33. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-6.77.

Sierra Oncology's EPS (Basic) for the three months ended in Mar. 2022 was $-1.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2022 was $-6.77.

Sierra Oncology's EPS without NRI for the three months ended in Mar. 2022 was $-1.33. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 was $-6.77.

During the past 3 years, the average EPS without NRIGrowth Rate was 38.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 35.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Sierra Oncology's highest 3-Year average EPS without NRI Growth Rate was 71.20% per year. The lowest was -37.70% per year. And the median was 29.90% per year.

Sierra Oncology EPS (Diluted) Historical Data

The historical data trend for Sierra Oncology's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sierra Oncology EPS (Diluted) Chart

Sierra Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EPS (Diluted)

Get a 7-Day Free Trial

-33.68

-30.16

-30.30

-7.70

-7.14

Sierra Oncology Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
EPS (Diluted)	Get a 7-Day Free Trial															-1.71	-1.67	-2.10	-1.67	-1.33

Competitive Comparison of Sierra Oncology's EPS (Diluted)

For the Biotechnology subindustry, Sierra Oncology's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sierra Oncology's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sierra Oncology's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sierra Oncology's PE Ratio falls into.

Sierra Oncology EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Sierra Oncology's Diluted EPS for the fiscal year that ended in Dec. 2021 is calculated as

Diluted EPS (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-94.659	-	0)	/	13.253
	=	-7.14

Sierra Oncology's Diluted EPS for the quarter that ended in Mar. 2022 is calculated as

Diluted EPS (Q: Mar. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-27.928	-	0)	/	20.966
	=	-1.33

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.77

Sierra Oncology (NAS:SRRA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sierra Oncology EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Sierra Oncology's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sierra Oncology (Sierra Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sierra Oncology Inc (NAS:SRRA) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1820 Gateway Drive, Suite 110, San Mateo, USA, 94404

Website

https://www.sierraoncology.com

Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.

Executives

Vivo Opportunity Fund Holdings, L.p.	director, 10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
William D. Turner	officer: Chief Reg & Tech Ops Officer	C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Mary Christina Thomson	officer: General Counsel	C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Joshua Richardson	director, 10 percent owner	C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Longitude Prime Fund, L.p.	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Gaurav Aggarwal	director, 10 percent owner	C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Vivo Opportunity Fund, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Andrew Sinclair	director	C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Craig A Collard	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Georgia Erbez	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459